<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Chris</forename><surname>Boodoo Bsc</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Julie</forename><forename type="middle">A</forename><surname>Perry</surname></persName>
						</author>
						<author>
							<persName><roleName>General Leung PhD</roleName><forename type="first">Karen</forename><forename type="middle">M</forename><surname>Cross</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Wanrudee</forename><surname>Isaranuwatchai</surname></persName>
							<email>isaranuwatcw@smh.ca</email>
						</author>
						<title level="a" type="main">Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6D7FD4CE8A4393155F2888B7F3CA339E</idno>
					<idno type="DOI">10.9778/cmajo.20180088</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-08-13T17:24+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Background: One of the most common (and costly) complications of diabetes are diabetic foot ulcers, which often result in lowerextremity amputation. Regular foot care can reduce complications; however, roughly half of Canadians with diabetes do not participate in screening. We sought to evaluate the economic effects of using telemonitoring for diabetic foot ulcer prevention using mathematical modelling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p>We used Markov modelling to compare current screening standards (standard care) to population-wide and targeted (highrisk) telemonitoring programs in a hypothetical cohort of Canadian patients aged 60 years. We varied the effectiveness (or outcome), defined as the proportion of diabetic foot ulcers prevented, to explore cost-effectiveness using model parameters from published literature and clinical experts.</p><p>Results: At 20%-40% effectiveness, population-based prevention resulted in 0.00399-0.00790 quality-adjusted life years (QALYs) gained per person over 5 years and an incremental cost of $479-$402 compared to standard care. At 15%-40% effectiveness, highrisk prevention resulted in a cost decrease per person over 5 years ($1.26-$25.55), with health benefits of 0.000207-0.00058 QALYs gained.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interpretation:</head><p>The use of telemonitoring in the diabetic lower extremity can offer patients better quality of life and can be costeffective compared to current Canadian screening practices. Future work should focus on developing and validating technologies based on objective outcome measures for remote monitoring of the diabetic foot.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>T he management and care of foot ulcers impose a tremendous burden on patients with diabetes and decrease their quality of life. <ref type="bibr" target="#b0">1</ref> Moreover, rates of lower-extremity amputation are 22 times higher among people with diabetes who have a foot ulcer than among the general population. <ref type="bibr" target="#b1">2</ref> Up to 85% of ulcer-related lower-extremity amputation procedures are preventable with frequent monitoring and prompt treatment. <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> However, only 51% of Canadians with diabetes had a foot screen in 2009, <ref type="bibr" target="#b5">6</ref> and foot care services essential to ulcer prevention such as chiropody and orthotic foot care are not funded in Ontario's health care system. <ref type="bibr" target="#b6">7</ref> This gap in care has led to sporadic prevention efforts and delayed care. <ref type="bibr" target="#b7">8</ref> Some barriers to frequent screening and monitoring such as travel distance, time limitations and unorganized referrals to specialists can be overcome by using technology to make medical services more accessible (known as telemedicine). Telemedicine is an increasingly popular mechanism for remote monitoring of chronic conditions and has been used successfully in diabetic populations to monitor (and decrease) hemoglobin A 1c levels, increase inpatient understanding of diabetes and improve cohesion among members of health care teams. <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref> Currently, there is mixed evidence on the effectiveness of telemedicine for monitoring diabetic foot ulcers, largely owing to a lack of large controlled studies. <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> Several technologies designed to diagnose ulcers have recently been developed and could potentially complement a telemedicine-based monitoring program. <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref> As the Canadian population ages, the strategic allocation of resources in our health care system becomes increasingly important. The global prevalence of diabetes is currently 8.5%</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research</head><p>(up from 4.8% in 1980) and is expected to increase. <ref type="bibr" target="#b27">28</ref> By 2020, an estimated 3.7 million Canadians will have diabetes, with an associated cost of nearly $17 billion. <ref type="bibr" target="#b28">29</ref> Diabetes accounted for 3.5% of Canadian health care spending in 2005, <ref type="bibr" target="#b28">29</ref> including an estimated $547 million on diabetic foot ulcer care, or $21 371 per prevalent case. <ref type="bibr" target="#b29">30</ref> The cost of a single ulcer case was $52 360, which included costs of hospital admissions, emergency department and clinic visits, drugs, dressings, and home and long-term care. <ref type="bibr" target="#b29">30</ref> Health care systems, which have traditionally been treatment-oriented and less focused on prevention, must adapt to meet increased demands and costs. Although multidisciplinary efforts were found to improve patient outcomes, <ref type="bibr" target="#b30">31</ref> the success of these initiatives is dependent on scale of resource allocation, additional personnel and coordination of diverse clinical teams including podiatrists, infectious disease specialists and plastic surgeons. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b31">32</ref> The lack of evidence for the efficacy of these specialized early-intervention programs makes funding them difficult from a policy-making perspective. <ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b33">34</ref> This study aimed to explore the preliminary cost-effectiveness of a telemedicine intervention for the prevention of diabetic foot ulcers. Specifically, we sought to determine the effectiveness threshold at which telemedicine prevention efforts could be cost-effective in Canada.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Analysis and reporting were done according to Canadian Agency for Drugs and Technologies in Health guidelines and Consolidated Health Economic Evaluation Reporting Standards. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparators</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intervention</head><p>The intervention was telemedecine by means of a device used to monitor the feet of people with diabetes remotely, based on number of annual visits to physicians recommended by the International Working Group on the Diabetic Foot (Supplementary Table <ref type="table" target="#tab_1">A1</ref>, Appendix 1, available at www.cmajopen.ca/ content/6/4/E486/suppl/DC1). <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b36">37</ref> We defined 2 approaches: a high-risk intervention (telemedicine device given to patients after their first diabetic foot ulcer) and a population-based intervention (device given before the formation of an ulcer).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Standard care in Canada (control)</head><p>We defined standard care in our cohort as the number of annual in-person visits to a physician, as recommended by the International Working Group on the Diabetic Foot and the Canadian Association of Wound Care. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b36">37</ref> We adjusted the number of visits per patient to the proportion of Canadians who received a foot screen in 2009 (51%). <ref type="bibr" target="#b5">6</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cohort and time horizon</head><p>The hypothetical cohort consisted of Canadians aged 60 years with diabetes and no history of ulceration. The cycle length was 4 months (the average time to ulcer healing <ref type="bibr" target="#b37">38</ref> ), and the time horizon was 5 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Model</head><p>We used a Markov model to simulate the history of diabetic foot ulcers in Canada using Microsoft Excel version 15.41 (Figure <ref type="figure" target="#fig_0">1</ref>). The model was debugged to validate functionality (see Appendix 1 for details). Cohort members started in state 1 (person with diabetes) and moved into predefined health states in 4-month cycles for 5 years. Each state had a 4-month cost estimate, and costs accumulated with time. Model validation is outlined in more detail in Appendix 1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effectiveness</head><p>We varied the effectiveness of primary prevention efforts from 5% to 40% at 3 possible states -low risk for ulcer formation, moderate risk for ulcer formation and healed ulcer <ref type="bibr" target="#b32">33</ref> -based on expert clinical opinion. We defined effectiveness as a decrease in the number of ulcers. The transition from a healed ulcer state to a recurrent ulcer state was decreased by 5%-40% (high-risk approach), and the transition from a lowrisk, moderate-risk or healed ulcer state to an ulcer state was decreased by 5%-40% (population-based approach).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Model parameters and outcomes</head><p>Model parameters are listed in Table <ref type="table" target="#tab_1">1</ref> and Supplementary Table <ref type="table" target="#tab_3">A2</ref>, Appendix 1. Outcomes were expressed in qualityadjusted life years (QALYs). <ref type="bibr" target="#b53">54</ref> Values were based on a review of utility values for type 2 diabetes <ref type="bibr" target="#b47">48</ref> (Supplementary Table <ref type="table" target="#tab_3">A2</ref>, Appendix 1). We used β distributions for all utility values, with a 1.5% discount rate. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b53">54</ref> Outcomes from our analysis were expressed as QALYs and incremental costeffectiveness ratios (ICERs) (which incorporate both the difference in costs between comparators in the numerator and the difference in QALYs in the denominator).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Resource use and costs</head><p>Costs and corresponding sources are listed in Table <ref type="table" target="#tab_1">1</ref>. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51</ref> We used γ distributions for all cost parameters, with 1.5% discount rate reported in 2015 Canadian dollars. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b53">54</ref> Details regarding how we derived costs are provided in Appendix 1. The cost of the telemedicine device was incurred once, and the cost of the telemedicine service was incurred every 4 months. The cost of diabetes was not included in this analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis</head><p>We explored cost-effectiveness by varying telemedicine effectiveness and comparing results to the standard-care model. We conducted separate analyses for the populationbased and high-risk approaches compared to the standardcare model. We calculated the ICER as the difference in cost divided by the difference in effectiveness. We calculated the difference in cost and in effectiveness as the cost or effectiveness of the intervention less the cost or effectiveness of standard care.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Probabilistic sensitivity analysis</head><p>We conducted Monte Carlo simulations of 1000 trials for both approaches versus standard care. We used γ distributions OPEN Research for cost parameters and β distributions for utility values. We used Dirichlet distributions for all multinomial transition parameters and β distributions for binomial transition parameters. <ref type="bibr" target="#b53">54</ref> At 30% effectiveness, we compared the probabilistic sensitivity analysis results for the high-risk and populationbased approaches on a cost-effectiveness plane. We constructed cost-effectiveness acceptability curves, with willingness-to-pay thresholds of $0-$100 000. A variation of the cost-effectiveness acceptability curve was also used. We identified proportions of simulations resulting in costeffectiveness at varying effectiveness levels for specific willingness-to-pay thresholds.</p><p>We conducted 1-way analyses to explore the effect on ICERs when key parameters were varied based on data in the literature and expert opinion (see Appendix 1 for details).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p>No ethics approval was required as the study did not involve human subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Population-based approach</head><p>A population-based approach to monitoring the feet of diabetic patients was both costlier and more effective than standard care (Table <ref type="table" target="#tab_3">2</ref>). When effectiveness of the telemedicine intervention increased, QALYs gained increased, and incremental costs decreased. If adopting a population-based approach decreased ulcer incidence by 20%-40%, the resulting health benefit was 0.00399-0.00790 QALYs gained per person. A population-based approach using telemedicine was a more widespread screening strategy than is currently in place in Canada, which translated into incremental costs of $479-$402 per person and ICERs of $120 087-$50 915.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>High-risk approach</head><p>People with diabetes who have had an ulcer are more likely than other people with diabetes to experience subsequent ulcers. Our second approach took this into account. We found    <ref type="bibr" target="#b42">43</ref> Amputation rate for low-risk diabetic foot ulcer 0.67 (0.3-0.77) Lavery et al., <ref type="bibr" target="#b38">39</ref> Prompers et al., <ref type="bibr" target="#b41">42</ref> Moulik et al. <ref type="bibr" target="#b43">44</ref> Amputation rate for moderate-risk diabetic foot ulcer 2.74 (0.063-8.54) Lavery et al., <ref type="bibr" target="#b38">39</ref> Prompers et al., <ref type="bibr" target="#b41">42</ref> Morbach et al., <ref type="bibr" target="#b44">45</ref> Oyibo et al. <ref type="bibr" target="#b45">46</ref> Amputation rate for recurrent diabetic foot ulcer 3.45 (0.68-3.45) Lavery et al., <ref type="bibr" target="#b38">39</ref> Örneholm et al. <ref type="bibr" target="#b42">43</ref> Mortality rate for low-risk diabetic foot ulcer 1.17 (1.01-2.73) Prompers et al., <ref type="bibr" target="#b41">42</ref> Morbach et al. <ref type="bibr" target="#b44">45</ref> Mortality rate for moderate-risk diabetic foot ulcer 3.26 (3.26-8.07) Prompers et al., <ref type="bibr" target="#b41">42</ref> Morbach et al. <ref type="bibr" target="#b44">45</ref> Mortality rate for recurrent diabetic foot ulcer 3.26 (3.26-8.07) Prompers et al., <ref type="bibr" target="#b41">42</ref> Örneholm et al., <ref type="bibr" target="#b42">43</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OPEN</head><p>Research that screening a high-risk population was slightly less costly and more effective than standard care at 15% effectiveness (Table <ref type="table" target="#tab_1">1</ref>). As expected, when effectiveness of ulcer prevention increased, there was also an increase in cost savings and QALYs gained. Over 5 years with effectiveness of 15%-40%, the health benefit was 0.000207-0.00058 QALYs gained per person, whereas costs decreased by $1.26-$25.55 per person.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity analysis</head><p>The majority of Monte Carlo simulations for the populationbased approach resulted in more QALYs gained and higher costs since more people were screened (Figure <ref type="figure" target="#fig_2">2</ref>). We also found that some simulations for both approaches resulted in fewer QALYs gained than the standard-care model, which is attributable to uncertainty in utility values. The costs in these cases were consistent with simulations that resulted in QALYs gained. We also conducted Monte Carlo simulations for all models (see Appendix 1 for details).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identifying highest probability of cost-effectiveness</head><p>Although the population-based approach prevented more ulcers, resulting in more QALYs gained, the cost of imple-menting such an approach is intuitively higher. To determine which intervention was more likely to have a lower ICER, we calculated the probability of cost-effectiveness for both approaches at 30% effectiveness. The results showed that a high-risk screening strategy had a higher probability than the population-based approach of being cost-effective at all willingness-to-pay thresholds (Figure <ref type="figure" target="#fig_1">3</ref>). At a threshold of $50 000, the high-risk and population-based approaches had a probability of cost-effectiveness of 92% and 25%, respectively. At a threshold of $100 000, the corresponding probability values were 86% and 60%. We next varied effectiveness levels at defined willingness-to-pay thresholds (Figure <ref type="figure" target="#fig_3">4</ref>). Not surprisingly, increasing the effectiveness of the intervention increased the probability of cost-effectiveness for both the high-risk and the population-based approach. Further analyses summarizing the effects of varying parameters related to cost of telemedicine, foot ulcer state utility values and ulcer incidence rates can be found in Supplementary Figures <ref type="figure" target="#fig_0">A1</ref> and<ref type="figure" target="#fig_2">A2</ref>, Appendix 1. Influential parameters were utility values for healed ulcers, active ulcers and no history of ulceration, and incidence rates for low-risk, moderate-risk and recurrent ulcers.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OPEN</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interpretation</head><p>In this work, we sought to evaluate the health and economic effects of using telemedicine to prevent diabetic foot ulcers. Although the absolute effect of telemedicine-based screening on ulcer incidence is unknown without clinical data, the potential health benefit associated with population-based screening was appreciable, ranging from 0.00399 to 0.00790 QALYs gained per person at a conservative effectiveness of 20%-40%. For context, an increase in QALYs of 0.0032-0.0095 per person over a lifetime was reported for screening for hepatitis C in Canada. <ref type="bibr" target="#b54">55</ref> However, populationbased screening is a more widespread strategy than is currently in place in Canada and would result in incremental costs of $479-$402 (2015 dollars) per person over 5 years. In contrast, we found that using telemedicine following a patient's first ulcer had a high probability of being costeffective while also slightly increasing quality of life (0.000207-0.00058 QALYs gained per person; decreased costs of $1.26-$25.55 per person at 15%-40% effectiveness). Cost savings were due to a reduction in ulcer recurrence and complications. Fewer screening devices are required in the high-risk approach (reducing upfront costs to the health care system), and targeting a group of patients with higher chances of ulcer formation eliminates waste.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p>Our analysis was based on data from various sources, but there is a lack of data on the prevalence of diabetic foot ulcer and associated costs in Canada. We used conservative estimates for ulcer incidence to avoid inflated results, and therefore our models may have underestimated the impact of telemedicine. <ref type="bibr" target="#b38">39</ref> In addition, we sourced the utility value for a healed ulcer from a different study than that for the other health states, as Beaudet and colleagues <ref type="bibr" target="#b47">48</ref> did not report such value. This uncertainty may increase or decrease the impact of Varying the effectiveness of the telemedicine intervention influences the probability of cost-effectiveness at given willingness-to-pay thresholds. At a willingness-to-pay threshold of $0 (A), $20 000 (B) and $50 000 (C), the high-risk approach has a higher probability of costeffectiveness than the population-based approach. At a willingness-to-pay threshold of $100 000 (D) and effectiveness above 15%, the population-based approach has a higher probability of cost-effectiveness than the high-risk approach.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OPEN</head><p>CMAJ OPEN, 6(4) E493</p><p>Research telemedicine (see 1-way analysis in Supplementary Figures <ref type="figure" target="#fig_0">A1</ref> and<ref type="figure" target="#fig_2">A2</ref>, Appendix 1). Moreover, costing data available for this study do not encompass all costs associated with ulcers. For example, costs of the "ulcer state" in our model included only the cost of physician services and hospital-based acute care. However, not all ulcers are treated on an inpatient basis.</p><p>Including outpatient clinic and home care costs would likely result in greater cost-effectiveness, but data in these realms of patient care are not available. Furthermore, indirect costs from a societal perspective, such as loss of productivity <ref type="bibr" target="#b55">56</ref> and travel costs incurred by the patient, were not included.</p><p>Our models represent simplified representations of diabetic foot ulcers and do not include the potential for infection or surgical débridement. <ref type="bibr" target="#b2">3</ref> It is unknown how this would change our results. Furthermore, our cohort was based on observational studies with an average patient age of 60 years. However, foot ulcers occur in patients with diabetes across all age groups. <ref type="bibr" target="#b56">57</ref> Lower rates of ulcer incidence would increase ICERs, and higher rates would improve ICERs. Subgroup analyses should be explored in future studies. This analysis should be considered an early health technology assessment given the lack of important data on various parameters. The findings, however, represent an initial piece of evidence supporting a potential solution to a growing problem.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>Rising rates of diabetes have been likened to an impending global tsunami. <ref type="bibr" target="#b28">29</ref> Health care systems must find a way to refocus care away from the reactionary and turn toward prevention. The use of telemedicine in the diabetic lower extremity can be an economically attractive alternative to current screening practices in Canada. Future work should focus on developing and validating technologies based on objective outcome measures for remote telemedicine of the diabetic foot.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc>Figure 1: Markov model of diabetic foot ulcer incidence and progression. All states can also transition to the amputation state, and all states can be absorbed by the death state (not shown). See Appendix 1 for details on each health state.</figDesc><graphic coords="3,31.49,76.55,522.02,391.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 :</head><label>3</label><figDesc>Figure 3:Cost-effectiveness acceptability curve, which summarizes the impact of uncertainty on the results, showing the proportion of simulations that resulted in an incremental cost-effectiveness ratio less than a willingness-to-pay threshold (x-axis) for the high-risk and populationbased approaches at 30% effectiveness. These proportions can be interpreted as probability of cost-effectiveness, based on 1000 simulations. Note: QALY = quality-adjusted life year.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 :</head><label>2</label><figDesc>Figure 2:Cost-effectiveness plane of 1000 Markov simulations in both a high-risk approach and a population-based approach assuming a rate of effectiveness of diabetic foot ulcer prevention of 30%. Most of the simulations conclude that telemedicine screening results in a gain of quality-adjusted life years, whereas only the high-risk screening strategy results in cost savings to the health care system.</figDesc><graphic coords="6,65.01,76.83,454.94,241.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc>Figure 4:Varying the effectiveness of the telemedicine intervention influences the probability of cost-effectiveness at given willingness-to-pay thresholds. At a willingness-to-pay threshold of $0 (A), $20 000 (B) and $50 000 (C), the high-risk approach has a higher probability of costeffectiveness than the population-based approach. At a willingness-to-pay threshold of $100 000 (D) and effectiveness above 15%, the population-based approach has a higher probability of cost-effectiveness than the high-risk approach.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 : Summary of key model parameters over a 4-month period</head><label>1</label><figDesc></figDesc><table><row><cell>Variable/state</cell><cell>Value (range)</cell><cell>Source</cell></row><row><cell>Transition probability, %</cell><cell></cell><cell></cell></row><row><cell>Rate of development of low-risk diabetic</cell><cell>0.3 (0.3-0.41)</cell><cell>Lavery et al. 39</cell></row><row><cell>foot ulcer</cell><cell></cell><cell></cell></row><row><cell>Rate of development of moderate-risk</cell><cell>0.45 (0.45-2.18)</cell><cell>Lavery et al. 39</cell></row><row><cell>diabetic foot ulcer</cell><cell></cell><cell></cell></row><row><cell>Rate of development of recurrent</cell><cell>11.21 (7.17-15.66)</cell><cell>Armstrong et al., 40 Dubský et al. 41</cell></row><row><cell>diabetic foot ulcer</cell><cell></cell><cell></cell></row><row><cell>Healing rate for low-risk diabetic foot</cell><cell>45.71</cell><cell>Prompers et al. 42</cell></row><row><cell>ulcer</cell><cell></cell><cell></cell></row><row><cell>Healing rate for moderate-risk diabetic</cell><cell>32.32</cell><cell>Prompers et al. 42</cell></row><row><cell>foot ulcer</cell><cell></cell><cell></cell></row><row><cell>Healing rate for recurrent diabetic foot</cell><cell>11.51</cell><cell>Örneholm et al.</cell></row><row><cell>ulcer</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 : Estimated cost-effectiveness of high-risk and population-based approaches to diabetic foot ulcer prevention by means of telemedicine at varying levels of effectiveness</head><label>2</label><figDesc></figDesc><table><row><cell>RR for</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Incremental</cell></row><row><cell>development of</cell><cell>Effectiveness,</cell><cell></cell><cell></cell><cell>Incremental</cell><cell>Incremental</cell><cell>cost-effectiveness</cell></row><row><cell>diabetic foot ulcer</cell><cell>%*</cell><cell>QALYs</cell><cell>Cost, $ †</cell><cell>cost, $ †</cell><cell>effect, QALYs</cell><cell>ratio ‡</cell></row><row><cell cols="2">Standard-care approach</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.00</cell><cell>0</cell><cell>3.650710</cell><cell>732.42</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>High-risk approach</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.95</cell><cell>5</cell><cell>3.650777</cell><cell>740.12</cell><cell>7.70</cell><cell>0.000067</cell><cell>114 017.16</cell></row><row><cell>0.90</cell><cell>10</cell><cell>3.650847</cell><cell>735.69</cell><cell>3.27</cell><cell>0.000136</cell><cell>23 9864.99</cell></row><row><cell>0.85</cell><cell>15</cell><cell>3.650917</cell><cell>731.16</cell><cell>-1.26</cell><cell>0.000207</cell><cell>Dominant</cell></row><row><cell>0.80</cell><cell>20</cell><cell>3.650987</cell><cell>726.53</cell><cell>-5.89</cell><cell>0.000278</cell><cell>Dominant</cell></row><row><cell>0.75</cell><cell>25</cell><cell>3.651060</cell><cell>721.78</cell><cell>-10.63</cell><cell>0.000351</cell><cell>Dominant</cell></row><row><cell>0.70</cell><cell>30</cell><cell>3.651137</cell><cell>716.93</cell><cell>-15.49</cell><cell>0.000426</cell><cell>Dominant</cell></row><row><cell>0.65</cell><cell>35</cell><cell>3.651210</cell><cell>711.96</cell><cell>-20.46</cell><cell>0.000502</cell><cell>Dominant</cell></row><row><cell>0.60</cell><cell>40</cell><cell>3.651290</cell><cell>706.87</cell><cell>-25.55</cell><cell>0.000580</cell><cell>Dominant</cell></row><row><cell cols="2">Population-based approach</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.95</cell><cell>5</cell><cell>3.651713</cell><cell>1272.41</cell><cell>539.99</cell><cell>0.00100</cell><cell>538 425.36</cell></row><row><cell>0.90</cell><cell>10</cell><cell>3.652710</cell><cell>1252.67</cell><cell>519.25</cell><cell>0.00200</cell><cell>259 406.24</cell></row><row><cell>0.85</cell><cell>15</cell><cell>3.653767</cell><cell>1231.25</cell><cell>498.83</cell><cell>0.00300</cell><cell>166 490.29</cell></row><row><cell>0.80</cell><cell>20</cell><cell>3.654697</cell><cell>1211.17</cell><cell>478.75</cell><cell>0.00399</cell><cell>120 103.31</cell></row><row><cell>0.75</cell><cell>25</cell><cell>3.655680</cell><cell>1191.43</cell><cell>459.01</cell><cell>0.00497</cell><cell>92 330.60</cell></row><row><cell>0.70</cell><cell>30</cell><cell>3.656667</cell><cell>1172.06</cell><cell>439.64</cell><cell>0.00595</cell><cell>73 867.36</cell></row><row><cell>0.65</cell><cell>35</cell><cell>3.657637</cell><cell>1153.07</cell><cell>420.65</cell><cell>0.00693</cell><cell>60 725.94</cell></row><row><cell>0.60</cell><cell>40</cell><cell>3.658606</cell><cell>1134.48</cell><cell>402.06</cell><cell>0.00790</cell><cell>50 912.60</cell></row><row><cell cols="3">Note: QALY = quality-adjusted life year, RR = relative risk.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">*Proportion of ulcers prevented.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>†2015 Canadian dollars.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">‡Dominant = less costly and more effective.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct coords="8,46.62,506.04,238.40,6.86;8,55.50,514.05,229.47,6.86;8,55.50,522.05,158.85,6.97" xml:id="b0">
	<analytic>
		<title level="a" type="main">Importance of factors determining the low health-related quality of life in people presenting with a diabetic foot ulcer: the Eurodiale study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Siersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Thorsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Holstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1382" to="1387" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.62,530.05,238.41,6.86;8,55.50,538.05,229.31,6.86;8,55.50,546.05,171.95,6.97" xml:id="b1">
	<analytic>
		<title level="a" type="main">Trends in the incidence of lower extremity amputations in people with and without diabetes over a five-year period in the Republic of Ireland</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Buckley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Canavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">41492</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.51,554.05,238.48,6.86;8,55.50,562.05,213.03,6.97" xml:id="b2">
	<analytic>
		<title level="a" type="main">Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Bowering K, Embil JM. Foot care</title>
	</analytic>
	<monogr>
		<title level="j">Can J Diabetes</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="145" to="149" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.62,570.05,238.36,6.86;8,55.50,578.05,229.50,6.86;8,55.50,586.05,201.54,6.97" xml:id="b3">
	<analytic>
		<title level="a" type="main">International Working Group on the Diabetic Foot. IWGDF guidance on the prevention of foot ulcers in at-risk patients with diabetes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Van Netten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Lavery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Metab Res Rev</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="16" to="24" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.62,594.06,238.39,6.86;8,55.50,602.06,98.64,6.97" xml:id="b4">
	<analytic>
		<title level="a" type="main">Preventing foot ulcers in patients with diabetes</title>
		<author>
			<persName><forename type="first">N</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Lipsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page" from="217" to="228" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.51,610.06,238.52,6.97;8,55.50,618.06,229.65,6.86;8,55.50,626.06,179.66,6.86" xml:id="b5">
	<analytic>
		<title level="a" type="main">Diabetics care gaps and disparities in Canada. Ottawa: Canadian Institute for Health Information</title>
		<ptr target="https://secure.cihi.ca/estore/productFamily.htm" />
	</analytic>
	<monogr>
		<title level="m">?pf=PFC1387&amp;lang=en&amp;media=0</title>
		<imprint>
			<date type="published" when="2009">2009. 2017 Aug. 22</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.72,634.06,238.29,6.86;8,55.50,642.06,92.20,6.97" xml:id="b6">
	<analytic>
		<title level="a" type="main">Prevention of diabetic foot ulcers: the bottlenecks in the pathway</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Lysy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetic Foot Can</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="38" to="40" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.62,650.06,238.36,6.86;8,55.50,658.06,224.56,6.97" xml:id="b7">
	<analytic>
		<title level="a" type="main">The system of care for the diabetic foot: objectives, outcomes, and opportunities</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Barshes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sigireddi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Wrobel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabet Foot Ankle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">21847</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.62,666.06,238.39,6.86;8,55.50,674.07,229.49,6.86;8,55.50,682.07,86.35,6.97" xml:id="b8">
	<analytic>
		<title level="a" type="main">Implementing the chronic care model for improvements in diabetes care and education in a rural primary care practice</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Siminerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Piatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Zgibor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Educ</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="225" to="234" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.46,690.07,238.36,6.86;8,55.50,698.07,180.09,6.97" xml:id="b9">
	<analytic>
		<title level="a" type="main">Facilitating patients&apos; diabetes self-management: a primary care intervention framework</title>
		<author>
			<persName><forename type="first">W</forename><surname>Corser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nurs Care Qual</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="172" to="178" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,46.46,706.07,238.52,6.86;8,55.50,714.07,229.50,6.97;8,55.50,722.07,33.80,6.86" xml:id="b10">
	<analytic>
		<title level="a" type="main">A shared decision-making approach to telemedicine: engaging rural patients in glycemic management</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Griffith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Siminerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Payne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">103</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,74.35,238.52,6.86;8,315.01,82.36,229.64,6.86;8,315.01,90.36,213.10,6.97" xml:id="b11">
	<analytic>
		<title level="a" type="main">Efficacy of mobile apps to support the care of patients with diabetes mellitus: a systematic review and metaanalysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Bonoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>De Araújo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">P</forename><surname>Godói</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e4</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,98.36,238.55,6.86;8,315.01,106.36,207.55,6.97" xml:id="b12">
	<analytic>
		<title level="a" type="main">Feasibility study of home care wound management using telemedicine</title>
		<author>
			<persName><forename type="first">M</forename><surname>Terry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Halstead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Skin Wound Care</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="358" to="364" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,114.36,238.61,6.86;8,315.01,122.36,184.88,6.97" xml:id="b13">
	<analytic>
		<title level="a" type="main">Impact of tele-advice on community nurses&apos; knowledge of venous leg ulcer care</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ameen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Coll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Adv Nurs</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="583" to="594" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,130.36,238.38,6.86;8,315.01,138.36,224.95,6.97" xml:id="b14">
	<analytic>
		<title level="a" type="main">A pilot study on the potential of remote support to enhance wound care for nursing-home patients</title>
		<author>
			<persName><forename type="first">K</forename><surname>Vowden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vowden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Wound Care</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="481" to="488" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,146.36,238.58,6.86;8,315.01,154.36,221.73,6.97" xml:id="b15">
	<analytic>
		<title level="a" type="main">Pilot trial of telemedicine as a decision aid for patients with chronic wounds</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Dobke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bhavsar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gosman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Telemed J E Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="245" to="249" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,162.37,238.58,6.86;8,315.01,170.37,229.49,6.86;8,315.01,178.37,229.27,6.97" xml:id="b16">
	<analytic>
		<title level="a" type="main">The effectiveness of digital imaging and remote expert wound consultation on healing rates in chronic lower leg ulcers in the Kimberley region of Western Australia</title>
		<author>
			<persName><forename type="first">N</forename><surname>Santamaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Carville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ellis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Primary Intention</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="62" to="70" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,186.37,238.54,6.86;8,315.01,194.37,149.83,6.97" xml:id="b17">
	<analytic>
		<title level="a" type="main">Telehomecare: quality, perception, satisfaction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Finkelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Speedie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Demiris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Telemed J E Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="122" to="128" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,202.37,238.51,6.86;8,315.01,210.37,229.49,6.97;8,315.01,218.37,58.39,6.97" xml:id="b18">
	<analytic>
		<title level="a" type="main">The use of telemedicine in the management of diabetes-related foot ulceration: a pilot study</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Wilbright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Birke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Patout</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Skin Wound Care</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="232" to="238" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,226.37,238.54,6.86;8,315.01,234.37,229.62,6.86;8,315.01,242.38,120.16,6.97" xml:id="b19">
	<analytic>
		<title level="a" type="main">A randomized controlled trial comparing telemedical and standard outpatient monitoring of diabetic foot ulcers</title>
		<author>
			<persName><forename type="first">Bsb</forename><surname>Rasmussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Froekjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Bjerregaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1723" to="1729" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,250.38,238.54,6.86;8,315.01,258.38,229.61,6.86;8,315.01,266.38,182.91,6.97" xml:id="b20">
	<analytic>
		<title level="a" type="main">Comment on Rasmussen et al. A randomized controlled trial comparing telemedical and standard outpatient monitoring of diabetic foot ulcers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>David-Tchouda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Margier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="9" to="10" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,274.38,238.40,6.86;8,315.01,282.38,129.64,6.97" xml:id="b21">
	<analytic>
		<title level="a" type="main">Telemedicine in wound care: a review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chanussot-Deprez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Contreras-Ruiz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Skin Wound Care</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="78" to="82" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,290.38,238.50,6.86;8,315.01,298.38,229.52,6.86;8,315.01,306.38,229.51,6.97;8,315.01,314.38,52.70,6.86" xml:id="b22">
	<analytic>
		<title level="a" type="main">The role of telemedicine in wound care: a review and analysis of a database of 5,795 patients from a mobile woundhealing center</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Granick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Trial</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plast Reconstr Surg</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<date type="published" when="2016">2016</date>
			<pubPlace>Languedoc-Roussillon, France</pubPlace>
		</imprint>
	</monogr>
	<note>Suppl):248S-56S</note>
</biblStruct>

<biblStruct coords="8,305.96,322.39,238.52,6.86;8,315.01,330.39,229.50,6.97;8,315.01,338.39,47.14,6.86" xml:id="b23">
	<analytic>
		<title level="a" type="main">A systematic review of the use of telemedicine in plastic and reconstructive surgery and dermatology</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Vyas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Hambrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shakir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Plast Surg</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="736" to="768" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,346.39,238.54,6.86;8,315.01,354.39,229.52,6.86;8,315.01,362.39,161.45,6.97" xml:id="b24">
	<analytic>
		<title level="a" type="main">Assessment of signs of foot infection in diabetes patients using photographic foot imaging and infrared thermography</title>
		<author>
			<persName><forename type="first">Cevb</forename><surname>Hazenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Van Netten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Baal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="370" to="377" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,370.39,238.54,6.86;8,315.01,378.39,229.57,6.86;8,315.01,386.39,229.54,6.86;8,315.01,394.39,70.47,6.86" xml:id="b25">
	<monogr>
		<title level="m" type="main">Fully convolutional networks for diabetic foot ulcer segmentation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Goyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Reeves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rajbhandari</surname></persName>
		</author>
		<ptr target="https://arxiv.org/abs/1708.01928" />
		<imprint>
			<date type="published" when="2017-06">2017 Aug. 6. 2017 Aug. 18</date>
			<publisher>Cornell University Library</publisher>
			<pubPlace>Ithaca (NY</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">preprint</note>
</biblStruct>

<biblStruct coords="8,305.96,402.40,238.55,6.86;8,315.01,410.40,229.52,6.97;8,315.01,418.40,64.68,6.97" xml:id="b26">
	<analytic>
		<title level="a" type="main">Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Holtz-Neiderer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wendel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1042" to="1046" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.87,426.40,238.64,6.97;8,315.01,434.40,30.50,6.86" xml:id="b27">
	<monogr>
		<title level="m" type="main">Global report on diabetes: a summary</title>
		<author>
			<persName><forename type="first">G</forename><surname>Roglic</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<publisher>World Health Organization</publisher>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,442.40,238.54,6.97;8,315.01,450.40,52.48,6.86" xml:id="b28">
	<monogr>
		<title level="m" type="main">An economic tsunami: the cost of diabetes in Canada</title>
		<imprint>
			<date type="published" when="2009">2009</date>
			<publisher>Canadian Diabetes Association</publisher>
			<pubPlace>Toronto</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,458.40,238.54,6.86;8,315.01,466.40,199.84,6.97" xml:id="b29">
	<analytic>
		<title level="a" type="main">Economic burden of illness associated with diabetic foot ulcers in Canada</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Hopkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harlock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,474.40,238.53,6.86;8,315.01,482.41,151.71,6.97" xml:id="b30">
	<analytic>
		<title level="a" type="main">Literature review on the management of diabetic foot ulcer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Yazdanpanah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nasiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adarvishi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="37" to="53" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,490.41,238.54,6.86;8,315.01,498.41,229.43,6.86;8,315.01,506.41,229.47,6.86;8,315.01,514.41,154.00,6.97" xml:id="b31">
	<analytic>
		<title level="a" type="main">International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Hinchliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jrw</forename><surname>Brownrigg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Apelqvist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Metab Res Rev</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="37" to="44" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,522.41,238.57,6.86;8,315.01,530.41,229.51,6.86;8,315.01,538.41,194.36,6.97" xml:id="b32">
	<analytic>
		<title level="a" type="main">International Working Group on the Diabetic Foot. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Van Netten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Lavery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Metab Res Rev</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="84" to="98" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,546.41,238.56,6.86;8,315.01,554.41,229.53,6.97;8,315.01,562.42,43.77,6.86" xml:id="b33">
	<analytic>
		<title level="a" type="main">Complex interventions for preventing diabetic foot ulceration</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Hoogeveen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><surname>Dorresteijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dmw</forename><surname>Kriegsman</surname></persName>
		</author>
		<idno>CD007610</idno>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="issue">8</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,570.42,238.46,6.97;8,315.01,578.42,208.22,6.86" xml:id="b34">
	<monogr>
		<title level="m" type="main">Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: Canadian Agency for Drugs and Technologies in Health</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,586.42,238.54,6.86;8,315.01,594.42,229.59,6.86;8,315.01,602.42,229.46,6.86;8,315.01,610.42,229.42,6.86;8,315.01,618.42,229.50,6.86;8,315.01,626.42,105.10,6.97" xml:id="b35">
	<analytic>
		<title level="a" type="main">ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) -explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force</title>
		<author>
			<persName><forename type="first">D</forename><surname>Husereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Petrou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="231" to="250" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,306.15,634.42,238.32,6.86;8,315.01,642.43,229.40,6.86;8,315.01,650.43,229.50,6.86;8,315.01,658.43,229.40,6.86;8,315.01,666.43,228.59,6.86;8,315.01,674.43,192.63,6.86" xml:id="b36">
	<monogr>
		<title level="m" type="main">Best practice recommendations for the prevention and management of diabetic foot ulcers. North York (ON): Wounds Canada</title>
		<author>
			<persName><forename type="first">M</forename><surname>Botros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuhnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Embil</surname></persName>
		</author>
		<ptr target="https://www.woundscanada.ca/docman/public/health-care-professional/bpr-workshop/895-wc-bpr-prevention-and-management-of-diabetic-foot-ulcers-1573r1e-final/file" />
		<imprint>
			<date type="published" when="2017-05-15">2018 Jan. 24. 2017 May 15</date>
			<publisher>Canadian Association of Wound Care</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,682.43,238.54,6.86;8,315.01,690.43,173.33,6.97" xml:id="b37">
	<analytic>
		<title level="a" type="main">Determinants and estimation of healing times in diabetic foot ulcers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zimny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pfohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Diabetes Complications</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="327" to="332" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="8,305.96,698.43,238.57,6.86;8,315.01,706.43,229.51,6.86;8,315.01,714.43,229.51,6.86;8,315.01,722.44,146.69,6.97" xml:id="b38">
	<analytic>
		<title level="a" type="main">Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Lavery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="154" to="156" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>International Working Group on the Diabetic Foot</note>
</biblStruct>

<biblStruct coords="9,46.46,72.33,238.53,6.86;9,55.50,80.33,114.30,6.97" xml:id="b39">
	<analytic>
		<title level="a" type="main">Diabetic foot ulcers and their recurrence</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajm</forename><surname>Boulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="2367" to="2375" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,88.33,238.54,6.86;9,55.50,96.33,229.54,6.97;9,55.50,104.33,73.81,6.97" xml:id="b40">
	<analytic>
		<title level="a" type="main">Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dubský</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jirkovská</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Wound J</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="555" to="561" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,112.33,238.54,6.86;9,55.50,120.33,229.47,6.86;9,55.50,128.34,229.50,6.97;9,55.50,136.34,22.28,6.86" xml:id="b41">
	<analytic>
		<title level="a" type="main">Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The Eurodiale Study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Prompers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schaper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Apelqvist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="747" to="755" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,144.34,238.56,6.86;9,55.50,152.34,229.51,6.97;9,55.50,160.34,22.28,6.86" xml:id="b42">
	<analytic>
		<title level="a" type="main">Recurrent and other new foot ulcers after healed plantar forefoot diabetic ulcer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Örneholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Apelqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Larsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Wound Repair Regen</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="309" to="315" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.60,168.34,238.49,6.86;9,55.50,176.34,209.49,6.97" xml:id="b43">
	<analytic>
		<title level="a" type="main">Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Moulik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mtonga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Gill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="491" to="494" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,184.34,238.57,6.86;9,55.50,192.34,229.47,6.86;9,55.50,200.34,109.49,6.97" xml:id="b44">
	<analytic>
		<title level="a" type="main">Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade</title>
		<author>
			<persName><forename type="first">S</forename><surname>Morbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Furchert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Gröblinghoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2021" to="2027" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,208.35,238.37,6.86;9,55.50,216.35,229.54,6.86;9,55.50,224.35,111.24,6.97" xml:id="b45">
	<analytic>
		<title level="a" type="main">The effects of ulcer size and site, patient&apos;s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Oyibo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Jude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tarawneh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="133" to="138" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,232.35,238.53,6.86;9,55.50,240.35,160.35,6.97" xml:id="b46">
	<analytic>
		<title level="a" type="main">Major lower extremity amputation: outcome of a modern series</title>
		<author>
			<persName><forename type="first">B</forename><surname>Aulivola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Hile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Hamdan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Surg</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="395" to="399" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,248.35,238.56,6.86;9,55.50,256.35,167.85,6.97" xml:id="b47">
	<analytic>
		<title level="a" type="main">Review of utility values for economic modeling in type 2 diabetes</title>
		<author>
			<persName><forename type="first">A</forename><surname>Beaudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Clegg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Thuresson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="462" to="470" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,264.35,238.53,6.86;9,55.50,272.35,229.52,6.86;9,55.50,280.35,90.42,6.97" xml:id="b48">
	<analytic>
		<title level="a" type="main">Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Redekop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stolk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Metab</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="549" to="556" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,288.36,238.35,6.97;9,55.50,296.36,229.32,6.86;9,55.50,304.36,229.40,6.86;9,55.50,312.36,42.01,6.86" xml:id="b49">
	<monogr>
		<title level="m" type="main">Schedule of benefits: physician services under the Health Insurance Act. Toronto: Ministry of Health and Long-Term Care</title>
		<ptr target="www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20151221.pdf" />
		<imprint>
			<date type="published" when="2016">2016. 2017 June 14</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,320.36,238.56,6.97;9,55.50,328.36,86.97,6.86" xml:id="b50">
	<monogr>
		<title level="m" type="main">Patient cost estimator: methodological notes and glossary</title>
		<imprint>
			<date type="published" when="2016">2016</date>
			<publisher>Canadian Institute for Health Information</publisher>
			<pubPlace>Ottawa</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,336.36,238.54,6.86;9,55.50,344.36,226.77,6.97" xml:id="b51">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of telemonitoring of diabetic foot ulcer patients</title>
		<author>
			<persName><forename type="first">I</forename><surname>Fasterholdt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstrøm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bsb</forename><surname>Rasmussen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Informatics J</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="245" to="258" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,46.46,352.36,238.56,6.86;9,55.50,360.36,229.60,6.86;9,55.50,368.37,209.45,6.86" xml:id="b52">
	<monogr>
		<title level="m" type="main">Financial statements: Ontario Telemedicine Network</title>
		<ptr target="https://otn.ca/wp-content/uploads/2016/10/otn-audited-financial-statements-2015-2016.pdf" />
		<imprint>
			<date type="published" when="2016-03-31">2016 Mar. 31. 2017 July 10</date>
			<publisher>Ernst &amp; Young</publisher>
			<pubPlace>Toronto</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,305.96,72.36,238.57,6.97;9,315.01,80.36,144.80,6.97" xml:id="b53">
	<monogr>
		<title level="m" type="main">Decision modelling for health economic evaluation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sculpher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Claxton</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2006">2006</date>
			<publisher>Oxford University Press</publisher>
			<pubPlace>Oxford (UK</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,305.96,88.37,238.53,6.86;9,315.01,96.37,124.52,6.97" xml:id="b54">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of screening for hepatitis C in Canada</title>
		<author>
			<persName><forename type="first">Wwl</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Feld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CMAJ</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="110" to="121" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,305.96,104.37,238.58,6.86;9,315.01,112.37,229.49,6.86;9,315.01,120.37,229.49,6.86;9,315.01,128.37,229.51,6.86" xml:id="b55">
	<monogr>
		<title level="m" type="main">Highlights: diabetes in Canada -facts and figures from a public health perspective</title>
		<ptr target="www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/highlights-saillants-eng.php" />
		<imprint>
			<date type="published" when="2011-12-15">2011 Dec. 15. 2017 May 10</date>
			<publisher>Ottawa: Public Health Agency of Canada</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct coords="9,305.96,136.37,238.52,6.86;9,315.01,144.37,229.52,6.86;9,315.01,152.37,229.53,6.86;9,315.01,160.37,221.96,6.86" xml:id="b56">
	<monogr>
		<title level="m" type="main">Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Margolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Malay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">J</forename><surname>Hoffstad</surname></persName>
		</author>
		<ptr target="www.ncbi.nlm.nih.gov/books/NBK65149/" />
		<imprint>
			<date type="published" when="2001">2006 to 2008. 2011. 2017 Aug. 1</date>
			<publisher>Agency for Healthcare Research and Quality</publisher>
			<biblScope unit="volume">2</biblScope>
			<pubPlace>Rockville (MD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
